A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2

A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2

Show other versions (1)

Bibliographic Details
Main Authors:	Yuanpei Xu, Yingcheng Wu, Siliang Zhang, Panpan Ma, Xinxin Jin, Zhou Wang, Min Yao, Erhao Zhang, Baorui Tao, Yongwei Qin, Hao Chen, Aifen Liu, Miaomiao Chen, Mingbing Xiao, Cuihua Lu, Renfang Mao, Yihui Fan
Format:	Article
Language:	English
Published:	Elsevier 2020-07-01
Series:	Cell Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2211124720309852

Similar Items

A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2
by: Yuanpei Xu, et al.
Published: (2019-12-01)

Hantavirus-Driven PD-L1/PD-L2 Upregulation: An Imperfect Viral Immune Evasion Mechanism
by: Martin J. Raftery, et al.
Published: (2018-12-01)

Editorial: Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies
by: Yiting Wang, et al.
Published: (2020-09-01)

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
by: Yiting Wang, et al.
Published: (2018-05-01)

Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma
by: Moo-Kon Song, et al.
Published: (2019-03-01)

The PD-1/PD-L pathway in rheumatic diseases
by: Shuo Zhang, et al.
Published: (2021-01-01)

Cis-platinum induces immunity evasion demonstrated by PD-L1 expression in bladder cancer cells
by: T. Hwang, et al.
Published: (2020-07-01)

Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer
by: Victor C. Kok, et al.
Published: (2020-02-01)

Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers
by: Aaron Prodeus, et al.
Published: (2015-01-01)

STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
by: Jung-Mao Hsu, et al.
Published: (2018-05-01)

Pan-Cancer Analysis Reveals Disrupted Circadian Clock Associates With T Cell Exhaustion
by: Yingcheng Wu, et al.
Published: (2019-10-01)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021-09-01)

Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma
by: Xingming Zhang, et al.
Published: (2019-04-01)

The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation
by: Man Shang, et al.
Published: (2021-03-01)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
by: Bogang Wu, et al.
Published: (2018-11-01)

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
by: Weiting Qin, et al.
Published: (2019-10-01)

Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion
by: Peixin Dong, et al.
Published: (2018-09-01)

Increased Nuclear Transporter KPNA2 Contributes to Tumor Immune Evasion by Enhancing PD-L1 Expression in PDAC
by: Kai-Xia Zhou, et al.
Published: (2021-01-01)

Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer
by: Di ZHANG, et al.
Published: (2019-06-01)

Expression and Clinical Significance of PD-1 and PD-L1 in Pulmonary Carcinoids
by: Mingbiao LI, et al.
Published: (2016-12-01)

Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells
by: Wei Zhang, et al.
Published: (2019-05-01)

PD-1/PD-L1 immunotherapy blockade in solid tumors: role of PD-1/PD-L1 in cancer disease progression
by: Li, Vivian
Published: (2021)

Downregulation of Immunosuppressive Molecules, PD-1 and PD-L1 but not PD-L2, in the Patients with Multiple Sclerosis
by: Mohammad Reza Javan, et al.
Published: (2016-08-01)

Progress in the treatment of Bladder Urothelial Carcinoma with PD-1 / PD-L inhibitor
by: Tao Zhang, et al.
Published: (2019-04-01)

Ocular adverse events in PD-1 and PD-L1 inhibitors
by: James Murray, et al.
Published: (2021-07-01)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
by: Chen Q, et al.
Published: (2018-08-01)

IL-21 Is an Accomplice of PD-L1 in the Induction of PD-1-Dependent Treg Generation in Head and Neck Cancer
by: Yi Zhao, et al.
Published: (2021-05-01)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
by: Ana Bocanegra, et al.
Published: (2020-08-01)

Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
by: Liudmila Spirina, et al.
Published: (2021-09-01)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
by: Chen CY, et al.
Published: (2018-07-01)

The PD-1:PD-L1 axis in Inflammatory Arthritis
by: Mary Canavan, et al.
Published: (2021-01-01)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
by: Jakub Litak, et al.
Published: (2019-10-01)

PD-1/PD-L1 Inhibitors in Cervical Cancer
by: Yuncong Liu, et al.
Published: (2019-02-01)

Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors
by: Jiangang Sun, et al.
Published: (2020-09-01)

Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
by: Sheng Chen, et al.
Published: (2021-01-01)

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
by: Jian-ye Zhang, et al.
Published: (2020-05-01)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
by: Hyun Tae Lee, et al.
Published: (2017-07-01)

Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival
by: Jingwei Liu, et al.
Published: (2020-01-01)

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
by: Rosemarie Tremblay-LeMay, et al.
Published: (2018-03-01)

Competition of L21 and L10 ordering in Pd2MnSe, Pd2FeSe, Pd2MnTe and Pd2FeTe Heusler alloys
by: Mengxin Wu, et al.
Published: (2019-03-01)